Opinion|Videos|March 21, 2025
Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment
Experts discuss the routine initiation of bridging therapy between leukapheresis and chimeric antigen receptor (CAR) T-cell infusion at their center; the pharmacist’s role in implementing this procedure; collaboration with the team on agent choice, dosage, and administration; and monitoring for disease control and adverse events as well as the observed impact of bridging therapy on outcomes post CAR T-cell therapy.
Advertisement
Video content above is prompted by the following:
At your center, is bridging therapy routinely initiated during the interval between leukapheresis and CAR T-cell infusion?
- If so, as a pharmacist, what is your role in implementing this procedure?
- With whom on the team do you communicate on choice of agent, dosage, administration frequency, and monitoring for disease control and adverse events?
- What impact of bridging therapy have you observed on outcomes post CAR T-cell therapy?
Advertisement
Related to this article
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
5